• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一家三级护理中心的隐匿性肝性脑病的患病率。

Prevalence of Covert Hepatic Encephalopathy in A Tertiary Care Centre.

机构信息

Department of Gastroenterology, Institute of Medicine, Maharajgunj, Nepal.

Department of Internal Medicine, College of Medical Sciences, Chitwan, Nepal.

出版信息

JNMA J Nepal Med Assoc. 2020 Jan;58(221):29-32. doi: 10.31729/jnma.4809.

DOI:10.31729/jnma.4809
PMID:32335636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7580484/
Abstract

INTRODUCTION

Among patients with Hepatic Encephalopathy, prevalence of Minimal HE varies between 30-50%. Identifying patients with MHE has been shown to improve with medications and delay development of Overt HE, however only limited clinicians screen for MHE in patients due to time consuming neuropsychological and neurophysiological tests. The Number Connection Test is an easy way to evaluate patients to diagnose MHE. The aim of this study is to find out the prevalence of covert hepatic encephalopathy.

METHODS

The descriptive cross-sectional study was done to find out the prevalence of covert hepatic encephalopathy among patients with chronic liver disease. To diagnose Covert HE which included MHE as well, NCT was used in Devanagari script.

RESULTS

The prevalence of covert hepatic encephalopathy is found to be 56 (58.3%) at 90% confidence interval (58.23-58.37%). A total of 96 patients (71.9% male) were diagnosed as HE, with mean age of 49.6+11.8 years. The cause of CLD in 85 (88.5%) of these patients was alcohol, of which 76 (79.2%) consumed locally brewed alcohol. Of these 96 patients with HE, only 40 (41.7%) had overt HE. Among all these, maximum patients had MHE (37.5%).

CONCLUSIONS

Our study showed that although the prevalence of minimal HE is quite high among cirrhotics, they are usually missed in clinical practice due to absence of symptoms. Active screening with easy-to-administer tests, like Number Connection tests, can help identify patients with minimal HE and hence treat them early.

摘要

介绍

在肝性脑病患者中,轻微肝性脑病的患病率在 30-50%之间。已证实,识别出 MHE 患者可通过药物治疗改善,并延缓显性肝性脑病的发展,但由于神经心理学和神经生理学测试耗时,仅有有限的临床医生对患者进行 MHE 筛查。数字连接测试是一种评估患者以诊断 MHE 的简便方法。本研究旨在确定隐匿性肝性脑病的患病率。

方法

这项描述性横断面研究旨在确定慢性肝病患者中隐匿性肝性脑病的患病率。为了诊断包括 MHE 在内的隐匿性肝性脑病,使用了数字连接测试(NCT)的梵文字符。

结果

在 90%置信区间(58.23-58.37%)内,发现隐匿性肝性脑病的患病率为 56(58.3%)。共有 96 名(71.9%为男性)患者被诊断为 HE,平均年龄为 49.6+11.8 岁。这些患者中 85 例(88.5%)的 CLD 病因是酒精,其中 76 例(79.2%)饮用本地酿造的酒精。在这 96 名患有 HE 的患者中,仅有 40 名(41.7%)患有显性 HE。在所有这些患者中,最多的患者患有 MHE(37.5%)。

结论

我们的研究表明,尽管轻微肝性脑病在肝硬化患者中患病率相当高,但由于缺乏症状,在临床实践中通常会被漏诊。通过易于管理的测试(如数字连接测试)进行积极筛查,可以帮助识别出患有轻微肝性脑病的患者,并及早进行治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba5/7580484/598e9d5e6134/JNMA-58-221-29-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba5/7580484/598e9d5e6134/JNMA-58-221-29-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba5/7580484/598e9d5e6134/JNMA-58-221-29-g1.jpg

相似文献

1
Prevalence of Covert Hepatic Encephalopathy in A Tertiary Care Centre.在一家三级护理中心的隐匿性肝性脑病的患病率。
JNMA J Nepal Med Assoc. 2020 Jan;58(221):29-32. doi: 10.31729/jnma.4809.
2
Covert hepatic encephalopathy: not as minimal as you might think.隐匿性肝性脑病:并非如你想象的那么轻微。
Clin Gastroenterol Hepatol. 2012 Nov;10(11):1208-19. doi: 10.1016/j.cgh.2012.05.026. Epub 2012 Jun 19.
3
EncephalApp Stroop Test validation for the screening of minimal hepatic encephalopathy in Brazil.EncephalApp斯特鲁普测试在巴西用于筛查轻微肝性脑病的验证。
Ann Hepatol. 2022 Jan-Feb;27(1):100543. doi: 10.1016/j.aohep.2021.100543. Epub 2021 Sep 24.
4
Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy.验证简化动物命名测试作为隐匿性肝性脑病诊断的初步筛查工具。
Eur J Intern Med. 2019 Feb;60:96-100. doi: 10.1016/j.ejim.2018.08.008. Epub 2018 Aug 19.
5
Minimal hepatic encephalopathy in children with chronic liver disease: Prevalence, pathogenesis and magnetic resonance-based diagnosis.儿童慢性肝脏疾病中的轻微肝性脑病:患病率、发病机制和基于磁共振的诊断。
J Hepatol. 2017 Mar;66(3):528-536. doi: 10.1016/j.jhep.2016.10.026. Epub 2016 Nov 1.
6
Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Cross-Sectional, Clinicoepidemiological, Multicenter, Nationwide Study in India: The PREDICT Study.肝硬化患者轻微肝性脑病的患病率:一项在印度开展的横断面、临床流行病学、多中心、全国性研究:PREDICT研究
J Clin Exp Hepatol. 2019 Jul-Aug;9(4):476-483. doi: 10.1016/j.jceh.2018.09.009. Epub 2018 Oct 15.
7
Diagnosis of minimal hepatic encephalopathy in a tertiary care center from eastern Romania: validation of the psychometric hepatic encephalopathy score (PHES).罗马尼亚东部一家三级医疗中心对轻微肝性脑病的诊断:心理测量肝性脑病评分(PHES)的验证
Metab Brain Dis. 2016 Dec;31(6):1463-1471. doi: 10.1007/s11011-016-9878-y. Epub 2016 Jul 27.
8
[Minimal hepatic encephalopathy: a better diagnostic to improve prognostic].[轻微肝性脑病:改善预后的更佳诊断方法]
Presse Med. 2014 May;43(5):e127-33. doi: 10.1016/j.lpm.2013.09.016. Epub 2014 Apr 2.
9
Prevalence and Characteristics of Covert/Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Systematic Review and Meta-Analysis.肝硬化患者隐匿性/轻微肝性脑病的患病率及特征:系统评价和荟萃分析。
Am J Gastroenterol. 2024 Apr 1;119(4):690-699. doi: 10.14309/ajg.0000000000002563. Epub 2023 Oct 19.
10
[Progress in the diagnosis of minimal hepatic encephalopathy].
Zhonghua Gan Zang Bing Za Zhi. 2022 Jan 20;30(1):110-112. doi: 10.3760/cma.j.cn501113-20200605-00294.

引用本文的文献

1
Hepatic Encephalopathy among Patients with Chronic Liver Disease Admitted to the Department of Internal Medicine in a Tertiary Care Centre: A Descriptive Cross-sectional Study.三级医疗中心内科收治的慢性肝病患者中的肝性脑病:一项描述性横断面研究
JNMA J Nepal Med Assoc. 2023 Jul;61(263):580-583. doi: 10.31729/jnma.8206. Epub 2023 Jul 30.

本文引用的文献

1
Nepalese Homebrewed Alcoholic Beverages: Types, Ingredients, and Ethanol Concentration from a Nation Wide Survey.尼泊尔自酿酒精饮料:全国性调查中的类型、成分及乙醇浓度
J Nepal Health Res Counc. 2015 Jan-Apr;13(29):59-65.
2
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.慢性肝病中的肝性脑病:美国肝病研究协会和欧洲肝脏研究协会2014年实践指南
Hepatology. 2014 Aug;60(2):715-35. doi: 10.1002/hep.27210. Epub 2014 Jul 8.
3
Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines.
肝性脑病的神经生理学研究:ISHEN实践指南
Liver Int. 2009 Jul;29(6):789-96. doi: 10.1111/j.1478-3231.2009.02030.x.
4
Testing for minimal hepatic encephalopathy in the United States: An AASLD survey.美国轻微肝性脑病的检测:美国肝病研究学会的一项调查。
Hepatology. 2007 Mar;45(3):833-4. doi: 10.1002/hep.21515.
5
Neuropsychological and neurophysiological evaluation in cirrhotic patients with minimal hepatic encephalopathy undergoing liver transplantation.对接受肝移植的轻度肝性脑病肝硬化患者进行神经心理学和神经生理学评估。
Transplant Proc. 2005 Mar;37(2):1104-7. doi: 10.1016/j.transproceed.2004.12.265.
6
Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations.轻微肝性脑病:诊断、临床意义及建议
J Hepatol. 2005;42 Suppl(1):S45-53. doi: 10.1016/j.jhep.2004.11.028. Epub 2004 Dec 28.
7
Portal-systemic encephalopathy; neurological complications of liver disease.门体循环性脑病;肝病的神经并发症。
Lancet. 1954 Sep 4;267(6836):454-7.
8
Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites.终末期肝病模型(MELD)评分与肝性脑病(由脑电图和神经心理测试定义)及腹水的关系。
Am J Gastroenterol. 2003 Jun;98(6):1395-9. doi: 10.1111/j.1572-0241.2003.07466.x.
9
Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.肝性脑病——定义、命名、诊断及量化:1998年于维也纳召开的第11届世界胃肠病学大会工作小组最终报告
Hepatology. 2002 Mar;35(3):716-21. doi: 10.1053/jhep.2002.31250.
10
Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.亚临床肝性脑病可预测显性肝性脑病的发生。
Am J Gastroenterol. 2001 Sep;96(9):2718-23. doi: 10.1111/j.1572-0241.2001.04130.x.